Introduction: Malnutrition is frequently found in head and neck cancer (HNC) patients subjected to chemoradiotherapy. Furthermore, the condition can hinder therapy and increase patient mortality. Nutrition therapy may be given proactively and reactively before and during chemoradiotherapy, as a response to nutritional status deterioration. Early or proactive nutrition therapy is considered superior in minimizing weight loss and interruption days during chemoradiotherapy. Therefore, this study aims to explore the clinical impact of proactive and reactive nutrition therapies.Case Presentation: A total of 4 HNC patients were subjected to chemoradiotherapy and received nutrition therapy at different points. Approximately 2 patients received proactive nutrition therapy, while the other 2 underwent reactive nutrition after cancer treatment. Increased intake was achieved through administering oral nutrition supplements and supporting a nasogastric tube. Patients who received proactive nutrition therapy experienced less weight loss compared to reactive therapy. Delayed initiation of nutrition therapy resulted in a more pronounced weight loss. Therefore, it was crucial to maintain energy intake in line with established recommendations to effectively uphold the nutritional status of cancer patients.Conclusions: Proactive nutrition therapy should be provided to HNC patients before the commencement of cancer therapy.
{"title":"Proactive versus Reactive Nutrition Therapy in Head and Neck Cancer Patients Treated with Chemoradiotherapy: A Case Series","authors":"Dian Araminta Ramadhania, Diyah Eka Andayani, Wina Sinaga","doi":"10.33371/ijoc.v17i3.972","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.972","url":null,"abstract":"Introduction: Malnutrition is frequently found in head and neck cancer (HNC) patients subjected to chemoradiotherapy. Furthermore, the condition can hinder therapy and increase patient mortality. Nutrition therapy may be given proactively and reactively before and during chemoradiotherapy, as a response to nutritional status deterioration. Early or proactive nutrition therapy is considered superior in minimizing weight loss and interruption days during chemoradiotherapy. Therefore, this study aims to explore the clinical impact of proactive and reactive nutrition therapies.Case Presentation: A total of 4 HNC patients were subjected to chemoradiotherapy and received nutrition therapy at different points. Approximately 2 patients received proactive nutrition therapy, while the other 2 underwent reactive nutrition after cancer treatment. Increased intake was achieved through administering oral nutrition supplements and supporting a nasogastric tube. Patients who received proactive nutrition therapy experienced less weight loss compared to reactive therapy. Delayed initiation of nutrition therapy resulted in a more pronounced weight loss. Therefore, it was crucial to maintain energy intake in line with established recommendations to effectively uphold the nutritional status of cancer patients.Conclusions: Proactive nutrition therapy should be provided to HNC patients before the commencement of cancer therapy.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Putu Erika Paskarani, Ni Made Mahastuti, Silvia Https://sinta.ristekbrin.go.id/authors Khosasi, Made Dalika Nareswari
Background: According to epidemiological research conducted in Bali, nasopharyngeal carcinoma (NPC) is the most common cancer among males, accounting for 4.9% of total cases reported between 2017 and 2019. NPC is typically detected at stage IV, indicating the presence of distant metastasis by malignant cells. However, research on the role of Poly-ADP-Ribose Polymerase-1 (PARP-1) in this type of cancer is still limited. Therefore, this research aims to investigate the relationship between PARP-1 and the clinicopathological aspects of NPC.Methods: This research employed an analytical observational design with a cross-sectional approach. From January 2018 to July 2022, biopsy tissue samples were collected from NPC patients, strictly following predefined inclusion and exclusion criteria. The clinical data of these patients were extracted from electronic medical records. Subsequently, the collected samples were subjected to immunohistochemical staining for PARP-1. The interpretation of PARP-1 results was conducted using the H-Score method. Data were analyzed using statistical software, specifically SPSS version 25.Results: The results showed that high PARP-1 expression was detected in 18 samples (62.1%), while the low aspect was observed in 11 samples (37.9%). Independent T-test analysis was conducted for sex, age, and clinical stage. No significant difference was found in the mean PARP-1 H-score among groups based on gender, age, and lymph node enlargement, with p-values of 0.68, 0.71, and 0.74, respectively. However, a statistically significant association was found between PARP-1 expression and clinical stage (p=0.02, 95% CI 1.45 – 63.50). Multivariate analysis showed that sex, age, lymph node enlargement, and clinical stage accounted for 22.1% of the variation in PARP-1 expression, with the clinical stage demonstrating a significant correlation (p=0.02). Conclusions: The clinicopathological data of NPC indicate a male-to-female ratio of 3:1. It was discovered that clinical stages IVA and IVB were the most commonly observed stages. Statistically significant differences were found in the mean and proportion of PARP-1 H-scores across different clinical stages. Future reviews need to include other histological subtypes and employ a prospective research design to evaluate the relationship between PARP-1 and NPC.
背景:根据巴厘岛开展的流行病学研究，鼻咽癌(NPC)是男性中最常见的癌症，占2017年至2019年报告病例总数的4.9%。鼻咽癌通常在IV期被发现，表明存在恶性细胞的远处转移。然而，关于poly - adp -核糖聚合酶-1 (PARP-1)在这类癌症中的作用的研究仍然有限。因此，本研究旨在探讨PARP-1与鼻咽癌临床病理方面的关系。方法:本研究采用横断面分析观察设计。2018年1月至2022年7月，严格按照预先确定的纳入和排除标准，从NPC患者中采集活检组织样本。这些患者的临床资料从电子病历中提取。随后，收集的样品进行PARP-1免疫组织化学染色。采用H-Score法解释PARP-1结果。数据分析使用统计软件，特别是SPSS版本25。结果:PARP-1高表达18例(62.1%)，低表达11例(37.9%)。对性别、年龄、临床分期进行独立t检验分析。性别、年龄、淋巴结肿大组PARP-1 h -平均评分差异无统计学意义，p值分别为0.68、0.71、0.74。然而，PARP-1表达与临床分期有统计学意义(p=0.02, 95% CI 1.45 - 63.50)。多因素分析显示，性别、年龄、淋巴结肿大、临床分期占PARP-1表达变异的22.1%，与临床分期有显著相关性(p=0.02)。结论:鼻咽癌的临床病理资料显示男女比例为3:1。发现临床分期IVA和IVB是最常见的分期。PARP-1 h -评分在不同临床阶段的平均值和比例差异有统计学意义。未来的回顾需要包括其他组织学亚型，并采用前瞻性研究设计来评估PARP-1与NPC之间的关系。
{"title":"The Relationship Between Poly-ADP-Ribose Polymerase-1 (PARP-1) Expression with Clinicopathological Characteristics of Nasopharyngeal Carcinoma in Bali, Indonesia","authors":"Putu Erika Paskarani, Ni Made Mahastuti, Silvia Https://sinta.ristekbrin.go.id/authors Khosasi, Made Dalika Nareswari","doi":"10.33371/ijoc.v17i3.979","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.979","url":null,"abstract":"Background: According to epidemiological research conducted in Bali, nasopharyngeal carcinoma (NPC) is the most common cancer among males, accounting for 4.9% of total cases reported between 2017 and 2019. NPC is typically detected at stage IV, indicating the presence of distant metastasis by malignant cells. However, research on the role of Poly-ADP-Ribose Polymerase-1 (PARP-1) in this type of cancer is still limited. Therefore, this research aims to investigate the relationship between PARP-1 and the clinicopathological aspects of NPC.Methods: This research employed an analytical observational design with a cross-sectional approach. From January 2018 to July 2022, biopsy tissue samples were collected from NPC patients, strictly following predefined inclusion and exclusion criteria. The clinical data of these patients were extracted from electronic medical records. Subsequently, the collected samples were subjected to immunohistochemical staining for PARP-1. The interpretation of PARP-1 results was conducted using the H-Score method. Data were analyzed using statistical software, specifically SPSS version 25.Results: The results showed that high PARP-1 expression was detected in 18 samples (62.1%), while the low aspect was observed in 11 samples (37.9%). Independent T-test analysis was conducted for sex, age, and clinical stage. No significant difference was found in the mean PARP-1 H-score among groups based on gender, age, and lymph node enlargement, with p-values of 0.68, 0.71, and 0.74, respectively. However, a statistically significant association was found between PARP-1 expression and clinical stage (p=0.02, 95% CI 1.45 – 63.50). Multivariate analysis showed that sex, age, lymph node enlargement, and clinical stage accounted for 22.1% of the variation in PARP-1 expression, with the clinical stage demonstrating a significant correlation (p=0.02). Conclusions: The clinicopathological data of NPC indicate a male-to-female ratio of 3:1. It was discovered that clinical stages IVA and IVB were the most commonly observed stages. Statistically significant differences were found in the mean and proportion of PARP-1 H-scores across different clinical stages. Future reviews need to include other histological subtypes and employ a prospective research design to evaluate the relationship between PARP-1 and NPC.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"247 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Harry Akza Putrawan, Arif Santoso, Nur Zam Zam, Irma Fitriani, Zainul Muttaqin
Introduction: Lung cancer is still a major contributor to cancer mortality worldwide. More than 80–85% of cases are constituted by Non-Small Cell Lung Cancer (NSCLC), consisting of approximately 40% adenocarcinomas. The prevalence of T790M mutation also accounts for 30%–50% of resistance to first- and second-generation tyrosine kinase inhibitors (TKI) after 9-12 months of therapy. To overcome this health condition, osimertinib has emerged as a first-line target therapy for lung adenocarcinoma with Epidermal Growth Factor Receptor (EGFR) mutation. Therefore, this study aimed to determine the effectiveness of osimertinib administration as first-line therapy in adenocarcinoma patients with EGFR TKI mutation. Case Presentation: This study presented a case of 60-year-old woman with shortness of breath and cough accompanied by weight loss ± 10 kg in 3 months. Contrast chest MSCT (multislice computed tomography) scan showed a mass in the right lung accompanied by pleural and pericardial effusion. The results of the cytological examination of pleural fluid found a picture of adenocarcinoma. Furthermore, the diagnosis was continued by molecular examination of pleural fluid, and the results of the EGFR Exon 19 mutation were obtained. Based on the results of physical examination and several laboratory tests, a diagnosis of right pleural effusion and EGFR mutation lung adenocarcinoma was established.Conclusions: In this case, there was a clinical improvement after 8 months of osimertinib administration, along with enhancement in the control CT-SCAN. Osimertinib also showed the potential to extend progression-free survival by approximately 18.9 months compared to other generations of tyrosine kinase inhibitor therapy. This result was supported by the improvement of the clinical and performance status of patients in this case during osimertinib administration.
{"title":"Osimertinib as First-Line Therapy of Patients with Lung Adenocarcinoma EGFR TKI Mutation from Pleural Fluid Samples: A Case Report","authors":"Harry Akza Putrawan, Arif Santoso, Nur Zam Zam, Irma Fitriani, Zainul Muttaqin","doi":"10.33371/ijoc.v17i3.993","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.993","url":null,"abstract":"Introduction: Lung cancer is still a major contributor to cancer mortality worldwide. More than 80–85% of cases are constituted by Non-Small Cell Lung Cancer (NSCLC), consisting of approximately 40% adenocarcinomas. The prevalence of T790M mutation also accounts for 30%–50% of resistance to first- and second-generation tyrosine kinase inhibitors (TKI) after 9-12 months of therapy. To overcome this health condition, osimertinib has emerged as a first-line target therapy for lung adenocarcinoma with Epidermal Growth Factor Receptor (EGFR) mutation. Therefore, this study aimed to determine the effectiveness of osimertinib administration as first-line therapy in adenocarcinoma patients with EGFR TKI mutation. Case Presentation: This study presented a case of 60-year-old woman with shortness of breath and cough accompanied by weight loss ± 10 kg in 3 months. Contrast chest MSCT (multislice computed tomography) scan showed a mass in the right lung accompanied by pleural and pericardial effusion. The results of the cytological examination of pleural fluid found a picture of adenocarcinoma. Furthermore, the diagnosis was continued by molecular examination of pleural fluid, and the results of the EGFR Exon 19 mutation were obtained. Based on the results of physical examination and several laboratory tests, a diagnosis of right pleural effusion and EGFR mutation lung adenocarcinoma was established.Conclusions: In this case, there was a clinical improvement after 8 months of osimertinib administration, along with enhancement in the control CT-SCAN. Osimertinib also showed the potential to extend progression-free survival by approximately 18.9 months compared to other generations of tyrosine kinase inhibitor therapy. This result was supported by the improvement of the clinical and performance status of patients in this case during osimertinib administration.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rifaldy Nabiel Erisadana, Yehuda Tri Nugroho Supranoto, Heni Fatmawati, Irawan Fajar Kusuma, Adrian Wibisono, Putu Ayu Laksmi Lestari
Background: Ablation modalities for the treatment of hepatocellular carcinoma (HCC) including microwave ablation (MWA) and radiofrequency ablation (RFA) are clinically important due to their numerous advantages. Several trials showed inconsistent results regarding safety and efficacy, making the comparison between MWA and RFA challenging. Therefore, this study aimed to enhance the evidence on treatment modalities regarding the clinical efficacy and safety of MWA compared to RFA in HCC patients. Methods: A systematic review and meta-analysis was conducted following the PRISMA guidelines. Subsequently, a literature search was carried out by PubMed, ScienceDirect, and Google Scholar for randomized controlled trials (RCTs) in HCC patients who passed through MWA compared to RFA. Quantitative analysis of pooled risk ratio with a 95% confidence interval was performed using Review Manager 5.4 software in a random-effects model or fixed-effects model forest plot.Results: Based on 9 RCTs included in the analysis, there were insignificant different results in terms of complete ablation rates (CA) [RR=1.01, 95%CI (0.99 to 1.03), p=0.47] and adverse events (AE) [RR=1.15, 95%CI (0.88 to 1.50), p=0.31]. However, lower incidence of local tumor progression (LTP) [RR=0.73, 95%CI (0.54 to 0.99), p=0.04], intrahepatic de novo lesions (IDL) [RR=0.90, 95%CI (0.81 to 1.00), p=0.05], and extrahepatic metastases (EHM) [RR=0.65, 95%CI (0.44 to 0.95), p=0.03] exhibited significant differences in MWA group.Conclusions: This meta-analysis provided evidence that MWA and RFA had equivalent CA rates and AE in HCC patients. However, MWA was considered superior to RFA due to a lower incidence of LTP, IDL, and EHM.
{"title":"Clinical Efficacy and Safety of Microwave Ablation Compared to Radiofrequency Ablation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Rifaldy Nabiel Erisadana, Yehuda Tri Nugroho Supranoto, Heni Fatmawati, Irawan Fajar Kusuma, Adrian Wibisono, Putu Ayu Laksmi Lestari","doi":"10.33371/ijoc.v17i3.988","DOIUrl":"https://doi.org/10.33371/ijoc.v17i3.988","url":null,"abstract":"Background: Ablation modalities for the treatment of hepatocellular carcinoma (HCC) including microwave ablation (MWA) and radiofrequency ablation (RFA) are clinically important due to their numerous advantages. Several trials showed inconsistent results regarding safety and efficacy, making the comparison between MWA and RFA challenging. Therefore, this study aimed to enhance the evidence on treatment modalities regarding the clinical efficacy and safety of MWA compared to RFA in HCC patients. Methods: A systematic review and meta-analysis was conducted following the PRISMA guidelines. Subsequently, a literature search was carried out by PubMed, ScienceDirect, and Google Scholar for randomized controlled trials (RCTs) in HCC patients who passed through MWA compared to RFA. Quantitative analysis of pooled risk ratio with a 95% confidence interval was performed using Review Manager 5.4 software in a random-effects model or fixed-effects model forest plot.Results: Based on 9 RCTs included in the analysis, there were insignificant different results in terms of complete ablation rates (CA) [RR=1.01, 95%CI (0.99 to 1.03), p=0.47] and adverse events (AE) [RR=1.15, 95%CI (0.88 to 1.50), p=0.31]. However, lower incidence of local tumor progression (LTP) [RR=0.73, 95%CI (0.54 to 0.99), p=0.04], intrahepatic de novo lesions (IDL) [RR=0.90, 95%CI (0.81 to 1.00), p=0.05], and extrahepatic metastases (EHM) [RR=0.65, 95%CI (0.44 to 0.95), p=0.03] exhibited significant differences in MWA group.Conclusions: This meta-analysis provided evidence that MWA and RFA had equivalent CA rates and AE in HCC patients. However, MWA was considered superior to RFA due to a lower incidence of LTP, IDL, and EHM.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135247671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nunki Puspita Utomo, Brenda Miriane Rustam, Sudharmadji Sudharmadji
Introduction: Multiple well-circumscribed round nodules, also known as “Cannonball” appearance in the lungs, are typically associated with specific pulmonary metastases. However, limited reports denote the finding, especially if correlated with primary squamous cell lung carcinoma in the younger population. This is the first case report in Indonesia of a 19-year-old male with primary squamous cell carcinoma in the lung and chest radiograph image mimicking a “Cannonball” appearance Case Presentation: A 19-year-old male was presented with a history of progressing hemoptysis for two weeks with no other abnormal respiratory symptoms but a reduction of vocal fremitus. The subject is an occasional smoker and had a history of lung tuberculosis in 2009 and a suprarenal or adrenal mass. X-ray imaging revealed multiple bilateral pulmonary nodules, mimicking the “Cannonball” appearance. A fine needle aspiration (FNA) biopsy of a nodule was done and interpreted to be primary squamous cell carcinoma. Symptomatic treatment was given and the subject was discharged on the fifth day. Conclusions: A “Cannonball” appearance or its mimic is not always typical to certain carcinoma based on what this case report finds. In the case of a tumor, radiograph findings should also be correlated with other supporting tests such as biopsy and clinical presentation.
{"title":"Atypical Radiology Imaging of Squamous Cell Lung Carcinoma: A Case Report and Narrative Review","authors":"Nunki Puspita Utomo, Brenda Miriane Rustam, Sudharmadji Sudharmadji","doi":"10.33371/ijoc.v17i2.958","DOIUrl":"https://doi.org/10.33371/ijoc.v17i2.958","url":null,"abstract":"Introduction: Multiple well-circumscribed round nodules, also known as “Cannonball” appearance in the lungs, are typically associated with specific pulmonary metastases. However, limited reports denote the finding, especially if correlated with primary squamous cell lung carcinoma in the younger population. This is the first case report in Indonesia of a 19-year-old male with primary squamous cell carcinoma in the lung and chest radiograph image mimicking a “Cannonball” appearance Case Presentation: A 19-year-old male was presented with a history of progressing hemoptysis for two weeks with no other abnormal respiratory symptoms but a reduction of vocal fremitus. The subject is an occasional smoker and had a history of lung tuberculosis in 2009 and a suprarenal or adrenal mass. X-ray imaging revealed multiple bilateral pulmonary nodules, mimicking the “Cannonball” appearance. A fine needle aspiration (FNA) biopsy of a nodule was done and interpreted to be primary squamous cell carcinoma. Symptomatic treatment was given and the subject was discharged on the fifth day. Conclusions: A “Cannonball” appearance or its mimic is not always typical to certain carcinoma based on what this case report finds. In the case of a tumor, radiograph findings should also be correlated with other supporting tests such as biopsy and clinical presentation.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79632546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Muhammad Habiburrahman, A. B. Putra, Muhammad Ilham Dhiya Rakasiwi
Background: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world. Surgical intervention remains the primary treatment option for resectable liver cancer. However, the low curative resection ratio, high metastatic ratio, and risk of recurrence make this treatment less than ideal. Additionally, the choice of liver transplantation is limited by the availability of donors. This literature review aimed to discuss the combination strategy of photothermal therapy and nanohybrid-based chemotherapy delivery, which are expected to address the challenges in HCC treatment. Methods: We conducted literature searches in Pubmed, Scopus, ProQuest, and Google Scholar using combined keywords such as “hepatocellular carcinoma”, “polyethylene glycol”, “doxorubicin”, “mesoporous silica”, “CuS”, “nanoparticle”, and “photothermal therapy”. Based on the assessment of validity and applicability aspects using modified Oxford CEBM (Center for Evidence-Based Management) and OHAT (Office of Health Assessment and Translation) checklist tools for preclinical studies, all the selected studies fulfilled the eligibility criteria. Results: Photothermal therapy promotes necrosis and apoptosis of HCC cells by ‘heating’ the cancer cells. Meanwhile, the chemotherapy agent doxorubicin, modified with mesoporous silica nanohybrids and encapsulated copper sulfate polyethylene glycol (PEG-DOX-MSN-CuS), enhances the efficiency and duration of drug circulation in the blood, reduces drug clearance, and minimizes retention by the reticuloendothelial system. By utilizing near-infrared light induction from photothermal therapy, doxorubicin can be slowly released, leading to significantly improved effectiveness. In vitro studies have demonstrated that this this combination strategy achieves over 90% HCC cell death at a chemotherapy concentration of 80 µg/mL, in conjunction with near-infrared light induction. The optimal release time for doxorubicin was recored at a concise 20 minutes. Conclusions: Given the numerous benefits associated with this combination of strategies, photothermal therapy using PEG-DOX-MSN-CuS holds significant expected to be a promising treatment for HCC.
{"title":"Combining Photothermal Therapy with A NanohybridBased Drug Delivery Strategy for Slow-Released Doxorubicin: A Treatment for Hepatocellular Carcinoma","authors":"Muhammad Habiburrahman, A. B. Putra, Muhammad Ilham Dhiya Rakasiwi","doi":"10.33371/ijoc.v17i2.964","DOIUrl":"https://doi.org/10.33371/ijoc.v17i2.964","url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world. Surgical intervention remains the primary treatment option for resectable liver cancer. However, the low curative resection ratio, high metastatic ratio, and risk of recurrence make this treatment less than ideal. Additionally, the choice of liver transplantation is limited by the availability of donors. This literature review aimed to discuss the combination strategy of photothermal therapy and nanohybrid-based chemotherapy delivery, which are expected to address the challenges in HCC treatment. Methods: We conducted literature searches in Pubmed, Scopus, ProQuest, and Google Scholar using combined keywords such as “hepatocellular carcinoma”, “polyethylene glycol”, “doxorubicin”, “mesoporous silica”, “CuS”, “nanoparticle”, and “photothermal therapy”. Based on the assessment of validity and applicability aspects using modified Oxford CEBM (Center for Evidence-Based Management) and OHAT (Office of Health Assessment and Translation) checklist tools for preclinical studies, all the selected studies fulfilled the eligibility criteria. Results: Photothermal therapy promotes necrosis and apoptosis of HCC cells by ‘heating’ the cancer cells. Meanwhile, the chemotherapy agent doxorubicin, modified with mesoporous silica nanohybrids and encapsulated copper sulfate polyethylene glycol (PEG-DOX-MSN-CuS), enhances the efficiency and duration of drug circulation in the blood, reduces drug clearance, and minimizes retention by the reticuloendothelial system. By utilizing near-infrared light induction from photothermal therapy, doxorubicin can be slowly released, leading to significantly improved effectiveness. In vitro studies have demonstrated that this this combination strategy achieves over 90% HCC cell death at a chemotherapy concentration of 80 µg/mL, in conjunction with near-infrared light induction. The optimal release time for doxorubicin was recored at a concise 20 minutes. Conclusions: Given the numerous benefits associated with this combination of strategies, photothermal therapy using PEG-DOX-MSN-CuS holds significant expected to be a promising treatment for HCC.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80802646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rizki Abri Laksono, Tanaya Ghinorawa, A. Danurdoro
Background: Prostate biopsy was used to diagnose and establish a therapy for prostate cancer (PCa). Instead of using conventional finger-guided prostate biopsy (FGPB) to approximate prostatic architecture, transrectal ultrasonography-guided biopsies of the prostate (TRUSGB) have become more popular nowadays because of offer direct visualization. However, the lack of availability of transrectal ultrasound probes in less-developed regions raises concerns regarding the need to diagnose patients with PCa. Moreover, different conclusions have been found from prior studies that examined the efficacy of both methods. This study aims to compare the accuracy of TRUSGB to FGPB in prostate cancer.. Methods: This study was done retrospectively from 50 medical records of PCa in the Urology Division of Sardjito Hospital from January 2009 until December 2013. Patients’ age, PSA value, digital rectal examination, and histopathological examination were analyzed. Results: The mean age was 65.18 ± 7.76 years in FGPB and 67.52 ± 10.79 years in TRUSGB group. The median PSA was 65.01 (range: 16.33–114.72) ng/mL in FGPB and 71.75 (range: 19.86– 123.47) ng/mL in TRUSGB. Abnormal DRE was found in 75.75% of patients in FGPB group and 70.58% in TRUSGB. Comparable cancer detection rates were found in the FGPB and TRUSGB groups (45.45% vs. 52.94%) (p = 0.136).Conclusions: The cancer detection rates for FGPB and TRUSGB procedures are comparable. This supports using FGPB as the first-line diagnostic technique, especially in low-resource situations where ultrasonography is unavailable.
背景:前列腺活检用于诊断前列腺癌(PCa)并建立治疗方法。代替传统的手指引导前列腺活检(FGPB)来接近前列腺结构，经直肠超声引导前列腺活检(TRUSGB)由于提供直接的可视化而变得越来越流行。然而，在欠发达地区，经直肠超声探头的缺乏引起了人们对前列腺癌诊断需求的关注。此外，从先前的研究中发现了不同的结论，这些研究检查了这两种方法的有效性。本研究旨在比较TRUSGB与FGPB在前列腺癌诊断中的准确性。方法:回顾性分析Sardjito医院泌尿科2009年1月至2013年12月的50例PCa病例。分析患者年龄、PSA值、直肠指检及组织病理学检查。结果:FGPB组平均年龄65.18±7.76岁，TRUSGB组平均年龄67.52±10.79岁。FGPB的中位PSA为65.01(范围:16.33-114.72)ng/mL, TRUSGB为71.75(范围:19.86 - 123.47)ng/mL。FGPB组DRE异常占75.75%，TRUSGB组DRE异常占70.58%。FGPB组和TRUSGB组的癌症检出率相当(45.45% vs. 52.94%) (p = 0.136)。结论:FGPB和TRUSGB的癌症检出率是相当的。这支持使用FGPB作为一线诊断技术，特别是在缺乏超声检查资源的情况下。
{"title":"Comparative Prostate Cancer Detection Rate of Transrectal Ultrasonography Guided versus Finger Guided Prostate Biopsy","authors":"Rizki Abri Laksono, Tanaya Ghinorawa, A. Danurdoro","doi":"10.33371/ijoc.v17i2.689","DOIUrl":"https://doi.org/10.33371/ijoc.v17i2.689","url":null,"abstract":"Background: Prostate biopsy was used to diagnose and establish a therapy for prostate cancer (PCa). Instead of using conventional finger-guided prostate biopsy (FGPB) to approximate prostatic architecture, transrectal ultrasonography-guided biopsies of the prostate (TRUSGB) have become more popular nowadays because of offer direct visualization. However, the lack of availability of transrectal ultrasound probes in less-developed regions raises concerns regarding the need to diagnose patients with PCa. Moreover, different conclusions have been found from prior studies that examined the efficacy of both methods. This study aims to compare the accuracy of TRUSGB to FGPB in prostate cancer.. Methods: This study was done retrospectively from 50 medical records of PCa in the Urology Division of Sardjito Hospital from January 2009 until December 2013. Patients’ age, PSA value, digital rectal examination, and histopathological examination were analyzed. Results: The mean age was 65.18 ± 7.76 years in FGPB and 67.52 ± 10.79 years in TRUSGB group. The median PSA was 65.01 (range: 16.33–114.72) ng/mL in FGPB and 71.75 (range: 19.86– 123.47) ng/mL in TRUSGB. Abnormal DRE was found in 75.75% of patients in FGPB group and 70.58% in TRUSGB. Comparable cancer detection rates were found in the FGPB and TRUSGB groups (45.45% vs. 52.94%) (p = 0.136).Conclusions: The cancer detection rates for FGPB and TRUSGB procedures are comparable. This supports using FGPB as the first-line diagnostic technique, especially in low-resource situations where ultrasonography is unavailable.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81708426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mujaddid Idulhaq, Fajar Baskoro Gardjito, Musa Fasa Roshada
Background: COVID-19 pandemic has led to a difficult condition for healthcare providers to maintain their service without risking their safety. Generally, patients were canceling their hospital visits as they feared COVID-19 transmission. This has led to a general decline in the number of patient visits, attending doctors, and elective surgeries. However, this may not be the same for oncologic orthopedic cases which are allowed to continue elective surgeries, and the patients still perceive their condition as urgently in need of treatment. This article aimed to compare the number of oncologic orthopedic surgeries before and during the COVID-19 pandemic and describe the profile of oncologic orthopedic surgery two years of the pandemic.Methods: This was a retrospective study comparing the total number of oncologic orthopedic patients undergoing elective surgery in a single center, Prof. Dr. R. Soeharso Orthopedic Hospital, Surakarta, Indonesia, from March 2019 to February 2022. The number of surgeries per month before the pandemic, in the first and second years of the COVID-19 pandemic, was described and compared with one-way ANOVA. The surgical procedures performed in these three years were also described.Results: The total of oncologic orthopedic surgeries before the COVID-19 pandemic was 390 cases in comparison to 374 cases in the first year and 355 cases in the second year of the pandemic. The average number of cases per month was 32.5 ± 6.4 before the pandemic compared to 31.2 ± 7.8 in the first year and 29.5 ± 6.4 cases per month in the second year of the pandemic. There was no significant difference (p = 0.59, Confidence Interval 95%). Sophisticated reconstruction surgery such as arthroplasty and megaprosthesis still took place during the pandemic. Conclusions: The trend in the number of oncologic orthopedic surgeries did not decline significantly during the COVID-19 pandemic.
{"title":"The Profile of Oncologic Orthopedic Surgery in 2 Years of COVID-19 Pandemic: A Single-Centered Study in Orthopedic Hospital","authors":"Mujaddid Idulhaq, Fajar Baskoro Gardjito, Musa Fasa Roshada","doi":"10.33371/ijoc.v17i2.926","DOIUrl":"https://doi.org/10.33371/ijoc.v17i2.926","url":null,"abstract":"Background: COVID-19 pandemic has led to a difficult condition for healthcare providers to maintain their service without risking their safety. Generally, patients were canceling their hospital visits as they feared COVID-19 transmission. This has led to a general decline in the number of patient visits, attending doctors, and elective surgeries. However, this may not be the same for oncologic orthopedic cases which are allowed to continue elective surgeries, and the patients still perceive their condition as urgently in need of treatment. This article aimed to compare the number of oncologic orthopedic surgeries before and during the COVID-19 pandemic and describe the profile of oncologic orthopedic surgery two years of the pandemic.Methods: This was a retrospective study comparing the total number of oncologic orthopedic patients undergoing elective surgery in a single center, Prof. Dr. R. Soeharso Orthopedic Hospital, Surakarta, Indonesia, from March 2019 to February 2022. The number of surgeries per month before the pandemic, in the first and second years of the COVID-19 pandemic, was described and compared with one-way ANOVA. The surgical procedures performed in these three years were also described.Results: The total of oncologic orthopedic surgeries before the COVID-19 pandemic was 390 cases in comparison to 374 cases in the first year and 355 cases in the second year of the pandemic. The average number of cases per month was 32.5 ± 6.4 before the pandemic compared to 31.2 ± 7.8 in the first year and 29.5 ± 6.4 cases per month in the second year of the pandemic. There was no significant difference (p = 0.59, Confidence Interval 95%). Sophisticated reconstruction surgery such as arthroplasty and megaprosthesis still took place during the pandemic. Conclusions: The trend in the number of oncologic orthopedic surgeries did not decline significantly during the COVID-19 pandemic.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76133849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Crizotinib is a drug designed to treat advanced NSCLC with ROS-1 rearrangement. Nevertheless, no reviews have assessed available studies to determine the efficacy and safety of first-line crizotinib against advanced NSCLC with ROS-1 rearrangement.Methods: PubMed, Cochrane Library, EBSCOHost, and ScienceDirect, were searched, filtered by inclusion and exclusion criteria, and read the full text. The researchers summarized and extracted efficacy as the primary outcome, including patients’ best response (complete response, partial response, stable disease, progressive disease, disease control rate, and objective response rate) and prognosis (overall survival rate and progression-free survival rate). Safety was also extracted as the secondary outcome.Results: Out of 91 articles electronically searched, four observational studies were included, extracted, and summarized descriptively. After full-text reading, entire studies were included. Across studies, the median PFS of the first line crizotinib varied from 14.9 months, 23.0 months, and 18.4 months with the median OS being 60 days to “Not Reach.” The patients’ best responses were similar among the studies. However, two out of four studies did not report the adverse event outcome. This study concluded that first-line crizotinib was safe.Conclusions: This systematic review suggests the potency of the first line of crizotinib therapy in advanced NSCLC patients. Regarding the current limitation of included studies, further higher quality with subsequent research in this scope is needed.
{"title":"Clinical Efficacy of Crizotinib as the First-Line Therapy of Advanced Non-Small-Cell Lung Carcinoma with ROS-1 Rearrangement: A Systematic Review","authors":"M. R. Fadhillah, J. Zaini","doi":"10.33371/ijoc.v17i2.933","DOIUrl":"https://doi.org/10.33371/ijoc.v17i2.933","url":null,"abstract":"Background: Crizotinib is a drug designed to treat advanced NSCLC with ROS-1 rearrangement. Nevertheless, no reviews have assessed available studies to determine the efficacy and safety of first-line crizotinib against advanced NSCLC with ROS-1 rearrangement.Methods: PubMed, Cochrane Library, EBSCOHost, and ScienceDirect, were searched, filtered by inclusion and exclusion criteria, and read the full text. The researchers summarized and extracted efficacy as the primary outcome, including patients’ best response (complete response, partial response, stable disease, progressive disease, disease control rate, and objective response rate) and prognosis (overall survival rate and progression-free survival rate). Safety was also extracted as the secondary outcome.Results: Out of 91 articles electronically searched, four observational studies were included, extracted, and summarized descriptively. After full-text reading, entire studies were included. Across studies, the median PFS of the first line crizotinib varied from 14.9 months, 23.0 months, and 18.4 months with the median OS being 60 days to “Not Reach.” The patients’ best responses were similar among the studies. However, two out of four studies did not report the adverse event outcome. This study concluded that first-line crizotinib was safe.Conclusions: This systematic review suggests the potency of the first line of crizotinib therapy in advanced NSCLC patients. Regarding the current limitation of included studies, further higher quality with subsequent research in this scope is needed.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76482427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Andinata, A. Bachtiar, P. Oktamianti, Jeremy Romeo Partahi, Mazaya Shafa Ainan Dini
Background: : Cancer is one of the main causes of death and increased morbidity in every country in the world. According to Global Cancer Observatory (GLOBOCAN) 2020 data, it is estimated that 19.3 million new cancer cases and nearly 10.0 million cancer deaths occurred in the world in 2020. Based on the same data, it is estimated that 396,914 new cancer cases and nearly 234,511 cancer deaths are estimated to occur in Indonesia. Dharmais National Cancer Hospital (DNCH) as a national cancer center is a miniature of cancer data in Indonesia. For this reason, researchers want to compare whether the data on the number and types of cancer in DNCH are the same as those in GLOBOCAN 2020.Methods: This research is a descriptive analysis with secondary data collection methods taken from medical records. The sampling technique was total sampling, univariate data analysis, namely new cases of cancer patients for the January-December 2021 period which are 2,382 cases.Results: The results showed that the same order in both data was only found in the first, second, and seventh order, namely breast cancer, cervical cancer, and non-Hodgkin’s lymphoma, respectively. However, the percentage of new cases of breast cancer in RSKD is much higher (2.5-folds) than in GLOBOCAN.Conclusion: There are several differences between the data on new cancer cases in the two data, which can be caused because DNCH has complete facilities, both for diagnostic and curative purposes, and examinations such as IHC and bone scans are only available at certain hospitals and one of them is DNCH.
{"title":"A Comparison of Cancer Incidences Between Dharmais Cancer Hospital and GLOBOCAN 2020: A Descriptive Study of Top 10 Cancer Incidences","authors":"B. Andinata, A. Bachtiar, P. Oktamianti, Jeremy Romeo Partahi, Mazaya Shafa Ainan Dini","doi":"10.33371/ijoc.v17i2.982","DOIUrl":"https://doi.org/10.33371/ijoc.v17i2.982","url":null,"abstract":"Background: : Cancer is one of the main causes of death and increased morbidity in every country in the world. According to Global Cancer Observatory (GLOBOCAN) 2020 data, it is estimated that 19.3 million new cancer cases and nearly 10.0 million cancer deaths occurred in the world in 2020. Based on the same data, it is estimated that 396,914 new cancer cases and nearly 234,511 cancer deaths are estimated to occur in Indonesia. Dharmais National Cancer Hospital (DNCH) as a national cancer center is a miniature of cancer data in Indonesia. For this reason, researchers want to compare whether the data on the number and types of cancer in DNCH are the same as those in GLOBOCAN 2020.Methods: This research is a descriptive analysis with secondary data collection methods taken from medical records. The sampling technique was total sampling, univariate data analysis, namely new cases of cancer patients for the January-December 2021 period which are 2,382 cases.Results: The results showed that the same order in both data was only found in the first, second, and seventh order, namely breast cancer, cervical cancer, and non-Hodgkin’s lymphoma, respectively. However, the percentage of new cases of breast cancer in RSKD is much higher (2.5-folds) than in GLOBOCAN.Conclusion: There are several differences between the data on new cancer cases in the two data, which can be caused because DNCH has complete facilities, both for diagnostic and curative purposes, and examinations such as IHC and bone scans are only available at certain hospitals and one of them is DNCH.","PeriodicalId":13489,"journal":{"name":"Indonesian Journal of Cancer","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76558800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：